Xencor (XNCR) Change in Accured Expenses (2013 - 2026)
Xencor (XNCR) posted quarterly Change in Accured Expenses of -$707000.0 for Q1 2026, up 77.58% year-over-year from -$398121.4 in Q1 2025, and down 110.18% quarter-over-quarter from $6.9 million in Q4 2025.
Analysis
Xencor (XNCR) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Change in Accured Expenses for 14 consecutive years, with -$707000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 77.58% year-over-year to -$707000.0; the TTM figure through Mar 2026 stood at $16.2 million (up 531.53% YoY), while the FY2025 annual figure was $13.8 million, up 417.37% from the prior year.
- Change in Accured Expenses eased to -$707000.0 in Q1 2026 per XNCR's latest filing, from $6.9 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.9 million in Q4 2025 and bottomed at -$10.1 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $756647.1 across 5 years, with a median of $2.9 million in 2022.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 581.72% — and 2025, when it jumped 212.15%.
- Xencor's Change in Accured Expenses stood at -$561000.0 in 2022, then tumbled by 61.85% to -$908000.0 in 2023, then sank by 581.72% to -$6.2 million in 2024, then surged by 212.15% to $6.9 million in 2025, then tumbled by 110.18% to -$707000.0 in 2026.
- Business Quant data shows XNCR's Change in Accured Expenses at -$707000.0 in Q1 2026, $6.9 million in Q4 2025, and $4.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 2.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.18 Mn |
| Mar 31, 2026 | -707,000.00 |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Mar 31, 2024 | -10.07 Mn |
| Dec 31, 2023 | -908,000.00 |
| Sep 30, 2023 | 6.03 Mn |
| Jun 30, 2023 | 3.30 Mn |
| Mar 31, 2023 | -3.59 Mn |
| Dec 31, 2022 | -561,000.00 |
| Sep 30, 2022 | 2.94 Mn |
| Jun 30, 2022 | 3.74 Mn |
| Mar 31, 2022 | -6.83 Mn |
| Dec 31, 2021 | -2.67 Mn |
| Sep 30, 2021 | 4.78 Mn |